Introduction
The
Seoul International New Pharmaceuticals Forum, which took its first step in
2009,
celebrates its 10th anniversary this year.
The
Seoul International New Pharmaceuticals Forum, which has been launched under the theme of "Beyond the Barrier of the Global New Pharmaceuticals"
at the first Forum,
has been dealing the major issues emerging in the
development of new pharmaceuticals
every year, such as △ Changes and challenges
in the new pharmaceuticals development
paradigm △ A new 10-year for Pharmaceutical and Bio fields △ Global innovative new
pharmaceuticals -
Customized medicines △ Creative economy era and R & D for new
pharmaceuticals △ Creative paradigm of pharmaceutical industry: Establishment of
a virtuous cycle structure for the development of new pharmaceuticals
△
Research of new diseases due to bacteria and virus, development of therapeutic
medicines and vaccines to control them △ Pharmaceutical industry, prior
occupation of
new market for therapeutic medicines to control rare diseases as
a new growth engine and
△ Development of new pharmaceuticals using medical big
data.
In
the meantime, the pharmaceutical industry has undergone drastic changes. In
particular,
domestic pharmaceutical companies have been making continuous
efforts to develop new pharmaceuticals. As a result, exports of complete
products of pharmaceuticals surpassed
$
2 billion for the first time last year. This was achieved in four years after
the export volume
exceeded $ 1 billion in 2013. In addition, the exports of
bio-pharmaceuticals, which have just
entered the market, recorded over $1
billion in 2016.
Of
course, there was a sharp decline in sales in 2010 due to the implementation of
the bilateral punishment against rebate payment. However, large domestic
pharmaceutical
companies, including Hanmi Pharm. Company, have concluded
contracts for technology
exportation with global Big-Pharma. companies one
after another, enhancing the possibility of
new pharmaceutical development.
In
response to this trend, the Government,
at the Pharmaceutical Industry Promotion Committee
early this year, has
disclosed that it will provide the implementation plan for detailed projects
for the
development of new pharmaceuticals using information and communication
technology (ICT) and
the development of next-generation bio-pharmaceuticals
such as the medicines for l dementia and
gene therapy in order take lead in the
4th industrial revolution.
At
the Seoul International New Pharmaceuticals Forum this year, you can find out
how Open
Innovation, a new conception
emerging at the backdrop of the 4th industrial revolution, shall be
applied to
the development of new pharmaceuticals. Currently, there are cases where the
results have reached clinical level through the inter-country projects with
Duke University and
University of Singapore.
In
addition, IBM will present a review on how you can use AI, the core technology
of the 4th
industrial revolution, in R
& D for new pharmaceuticals development. Further, you will be
furnished
with updated information about CAR-T of Novartis, the personally customized
cell therapy medicine, that has emerged as a new issue recently, as well
as AstraZeneca's 5R
framework aimed to improve the productivity of new pharmaceuticals development
researches.
The
10th Seoul International New Pharmaceuticals Forum will have the opportunity to
examine
how new technologies developing in the path of 4th industrial
revolution, can help develop new
pharmaceuticals through its application to
such development projects.
Overview
Title : The 10h Seoul International New Pharmaceuticals Forum
Theme : New Drug Development, Convergence with New Technology
Date : June 21st, 2018(Thu) / 09:00 ~ 16:00
Venue : Grand Ballroom, The Westin Chosun Hotel, Seoul
Host : The Financial News, Korea Research Institute of Chemical Technology
Supporters : Ministry of Health and Welfare, Ministry of Science and ICT,
National Institute of Food and Drug Safety Evaluation,
Korea Pharmaceutical and Bio-Pharma Manufacturers Association,
Korea Biotechnology Industry Organization,
Korea Research-based Pharmaceutical Industry Association
Inquiry : Seoul International New Pharmaceuticals Forum
Tel. 02-6965-0014 / Mail. iamkhs@fnnews.com
Time |
Section | Program | |
08:00 ~ 09:00 |
Registration |
Registration |
|
09:00 ~ 09:30 |
Opening Ceremony |
<Opening Remark> Jeon, Jae Ho Chairman & CEO, The Financial News <Congratulatory Remarks> Jeon, Hye Sook Member, Health&Welfare Committee, National Assembly Ryu, Young Jin Minister of Food and Drug Safety |
|
09:30 ~ 09:45 |
Keynote Address |
Kim, Sung SooPresident, Korea Research Institute of Chemical Technology |
|
09:45 ~ 10:25 |
Keynote Speech |
Patrick J. Casey Professor, Duke University Medical Center |
|
Session 1. Translational Research in Open Innovation |
|||
10:25 ~ 10:45 |
Speech |
Kim, Young Hwa Associate Director, AstraZeneca |
|
10:45 ~ 11:05 |
Lee, Kwang Ho Principal Investigator, Korea Research Institute of Chemical Technology |
||
11:05 ~ 11:25 |
Lee, Kyeong Professor, College of Pharmacy, Dongguk University |
||
11:25 ~ 11:45 |
Kim, Kyung Jin President & CEO, ST PHARM |
||
11:45 ~ 13:00 Luncheon |
|||
Session 2. Convergence Technology beyond Drug Discovery |
|||
13:00 ~ 14:00 |
Panel Discussion |
<Moderator> Han, Gyoon Hee Dean, College of Pharmacy, Yonsei University <Panel> Kim, Joo Young Manager, Health Industry Promotion Division, Ministry of Health & Welfare Lee, Sung Joo Founder, Orum Therapeutics Lee, Kwang Ho Principal Investigator, Korea Research Institute of Chemical Technology Hwang, Tae Ho Director, MRC of PNU Medical School |
|
14:00 ~ 14:30 |
Speech |
Cicero Nogueira Dos Santos Research Staff Member, IBM Research |
|
14:30 ~ 15:00 |
Cho, Byoung Chul Associate Professor, Yonsei Cancer Center |
||
15:00 ~ 15:30 |
Jeong, Jae Uk Fellow & Scientific Leader, GSK |
||
15:30 ~ 16:00 |
Hwang, Tae Ho Director, MRC of PNU Medical School |
※ The program is subject to change.
-
Kim, Sung Soo
President, Korea Research Institute of Chemical Technology
-
Patrick J. Casey
Professor of Pharmacology and Cancer Biology, Duke University Medical Center
-
Kim, Young Hwa
Associate Director, AstraZeneca
-
Lee, Kwang Ho
Principal Investigator, Korea Research Institute of Chemical Technology
-
Lee, Kyeong
Professor, Dongguk University, College of Pharmacy
-
Kim, Kyung Jin
President & CEO, ST PHARM
-
Han, Gyoon Hee
Dean, Yonsei University, College of Pharmacy
-
Kim, Joo Young
Manager, Health Industry Promotion Division, Ministry of Health & Welfare
-
Lee, Sung Joo
Founder, Orum Therapeutics
-
Cicero Nogueira dos Santos
Research Staff Member, IBM Research
-
Cho, Byoung Chul
Associate professor, Yonsei Cancer Center
-
Jeong, Jae Uk
Fellow & Scientific Leader, GSK
-
Hwang, Tae Ho
Director, MRC of PNU medical school

<Education> • Ph.D. in Chemistry, Korea Advanced Institute of Science and Technology, Daejeon, Korea (1985-1988 ) • M.S. in Chemistry Korea Advanced Institute of Science and Technology, Daejeon, Korea (1984-1985) • B.S.E. in Chemistry Education, Seoul National University, Seoul, Korea (1980- 1984) <Career> • President, Korea Research Institute of Chemical Technology( 2018- present) • Member of Board of Directors, National Research Foundation of Korea (2016- present) • Member of Board of Trustees, Vice President, Korea Chemical Society (2016-2017) • Chairman of Advisory Committee for Cutting-edge Fusion, Presidential Advisory Council on Science and Technology (2013-2014) • Director, R&D Planning Bureau, Ministry of Food and Drug Safety (2012) • Deputy Director General, Science, Technology and Innovation Office, Ministry of Science (2007-2008) • Vice President, Korea Research Institute of Chemical Technology (2008-2011) • Research Fellow, Korea Research Institute of Chemical Technology (1990-present) • Postdoctoral Research Associate, Department of Chemistry, Havard University (1988-1990)

<Education> 1978 B.A., Biology and Chemistry, Augustana College, Sioux Falls, SD. 1986 Ph.D., Biochemistry, Brandeis University, Waltham, MA. <Career> 1978 – 1981 Analytical Chemist, James Ford Bell Technical Center, Minneapolis, MN. 1981 – 1986 Graduate Fellow, Department of Biochemistry, Brandeis University, Waltham, MA. Research advisors - Dr. John Lowenstein and Dr. Robert Abeles. 1986 – 1990 Postdoctoral Fellow, Department of Pharmacology, U.T. Southwestern Medical Center, Dallas, TX. Research advisor - Dr. Alfred Gilman. 1990 – 1995 Assistant Professor, Department of Molecular Cancer Biology and Department of Biochemistry, Duke University Medical Center, Durham, NC. 1995 – 1999 Associate Professor, Department of Pharmacology and Cancer Biology and Department of Biochemistry, Duke University Medical Center 1997 – 2006 Director, Program in Molecular Cancer Biology, Duke University 1999 – 2006 Director, Center for Chemical Biology, Duke University Medical Center 1999 – Professor, Department of Pharmacology and Cancer Biology and Department of Biochemistry, Duke University Medical Center 2005 – Senior Vice Dean of Research, Duke-NUS Medical School, Singapore

<Education> 1999~2006 Weill Graduate School of Cornell Univ. Immunology, Ph.D 1995~1997 Seoul National Univ. Immunology, M.S. 1990~1994 Korea Univ. Biology, B.S. <Career> 2017~Present AstraZeneca, Medical Scientist, Associate Director 2014~2017 AstraZeneca, Asia Lead for External Sciences, Associate Director 2012~2014 AstraZeneca, External Collaborations, Senior Manager 2011~2012 Pfizer, World-wide BD & Innovation, R&D Business Development, Senior Manager 2009~2011 Pfizer, Asia R&D, Business Development, Manager 2008~2009 Green Cross Corp, R&D Strategy and Planning Team, Senior manager 2006~2008 Immunology and Rheumatology Merck Research Laboratories, Post-doctoral fellow

<Education> 2001~2003 Harvard University, Postdoctoral Researcher 1997~2001 The University of Alabama, Organic Chemistry Ph D. 1990~1992 Seoul National University, Organic Chemistry M.S. 1986~1990 Seoul National University, Chemistry B.S. <Career> 2012~Present Translational Research Institute of Novel Drug (TREND), Director 2012~Present Korea University of Science & Technology, Adjunct Professor 2011~Present Korea Research Institute of Chemical Technology, Principal Investigator 2008~2011 Avila Therapeutics, Program Team Head 2003~2008 Novartis Institutes for BioMedical Research, Inc., Research Investigator 1992~1997 CJ Co., Senior Research Associate

<Education> 1995~2000 Univ. of Georgia, Coll. of Pharm. Medicinal Chemistry Ph.D 1993~1995 Seoul National Univ. Coll. pharmaceutical chemistry M.S. 1989~1993 Ewha Womans Univ. pharmacy B.S. <Career> 2016~Present Archives of Pharmacal Research Editing Commission Assistant Member 2016~Present National Research Foundation of Korea, Bio Promotion Committee, Commissioner 2016~Present National Research Foundation of Korea, R&D Policy & Innovation, Director 2012~Present Open Translational Research Center, Chief 2009~Present Dongguk Univ., Coll. of Pharmacy, associate professor/ full professor 2009~2009 Korea Research Institute of Bioscience & Biotechnology, Head Researcher 2004~2008 Korea Research Institute of Bioscience & Biotechnology, Senior Researcher

<Education> 1996 Ph.D., Chemistry, Texas A&M University 1990 M.S., Chemistry, Sogang University 1988 B.S., Chemistry, Sogang University <Career> Current: President and CEO, ST PHARM Sr. Principal Scientist, Hoffmann-La Roche, Nutley, NJ, USA Postdoctoral Research Fellow, U. of California, Berkeley, CA, USA

<Education> 1984-1988: B.S. Industrial Pharmacy Seoul National University 1988-1990: M.S. medicinal Chemistry, Seoul National University 1992-1997: Ph.D. Organic Chemistry, The Pennsylvania State University <Career> 2004-present: Professor, Department of Biotechnology/ Department of Biotechnology Integrated OMICS for Biomedical Science, Yonsei University 2008-2010: Associate Dean, College of Life Science and Biotechnology 2011-2013: Head, Department of Biotechnology 2013-2015: Associate Dean (Planning), Underwood International College 2015-Present: Dean, College of Pharmacy 2016-2018: Senior Director, Korea Association of Pharmacy Education 2018-present: Chairman, Korea Association of Pharmacy Education

<Education> 2012 Kyungwon University, School of Oriental Medicine, Ph. D 1998 Soongsil University, Graduate School of Unification Policy Social Welfare, M.S. 1991 Dongguk University, School of Oriental Medicine, B.S. <Career> 2016~2018 Ministry of Health & Welfare, Health Industry Promotion Division, Manager 2013~2016 Ministry of Health & Welfare, Senior Support Division, Manager 2012~2013 Keimyung University, Medical school, Preventive Medicine, Research Professor 2011~2012 Ministry of Health & Welfare, Development of Comprehensive medical complex, Team Leader / Ministry of Health & Welfare, Improvement of health examination system, Team Leader 2010~2011 Korea Centers for Disease Control and Prevention, Research and development manager 2007~2010 Division of Health Industry Policy, Deputy Director 2005~2007 Prime Minister's Office, Health Industry Development Bureau

<Education> 2003~2005 Stanford University, Postdoctoral Researcher 1997~2003 University of California, Berkeley, Biophysics, Ph.D 1993~1997 Yonsei University, Biochemistry, B.S. 1994~1995 Salk Institute, Undergraduate Researcher 1994~1995 UC San Diego, Structural Biology, Exchange student <Career> 2016~Present Orum Therapeutics, Founder 2013~2016 Sanofi, Asia Pacific R&D, Head Researcher 2010~2013 Sanofi, Korea R&D Leader 2005~2010 LG Life Sciences, Deputy General Manager/ Computational Modeling Scientist

<Education> 2005~2009 Doctor of Science in Computer Science (Ph.D.), Pontifical Catholic University of Rio de Janeiro – PUC-Rio 2003~2005 Master of Science in Computer Science (M.Sc.), Military Institute of Engineering – IME 1998~2003 Bachelor in Mechanical Production Engineering, Regional University of Cariri – URCA <Career> 2015~present Research Staff Member, IBM Research, NY, USA 2012~2015 Research Staff Member, IBM Research-Brazil, International Business Machines (IBM) 2009~2012 Assistant Professor, University of Fortaleza – UNIFOR ※ Q&A e-mail : cicerons@us.ibm.com

<Education> 2005~2011 Yonsei Univ. Coll. of Medicine, Ph.D. 2003~2005 Yonsei Univ. Coll. of Medicine, M.S. 2000~2000 Harvard Medical School, Visiting student 1997~2001 Yonsei Univ. Coll. of Medicine, B.S. 1995~1996 Oregon State Univ., Biochemistry, Exchange student 1990~1997 Yonsei Univ. Coll. of Science, Biochemistry, B.S. <Career> 2014~Present Yonsei Cancer Center, Medical Oncology, Associate professor 2009~2013 Yonsei Cancer Center, Medical Oncology, Assistant professor 2008~2009 Yonsei Cancer Center, Medical Oncology, Instructor 2006~2007 Yonsei Cancer Center, Medical Oncology, Clinical Fellow 2002~2005 Severance Hospital, Internal Medicine, Resident 2001~2002 Asan Medical Center, Rotating Internship

<Education> 1996 Ph.D., Organic Chemistry, Purdue University 1988 M.S., Organic Chemistry, Sogang University, Seoul, Korea 1986 B.S., Chemistry, Sogang University, Seoul, Korea <Career> 1998 ~ current GSK Fellow, Scientific Leader, Medicinal Chemistry, PRR DPU, Immuno-Inflammation Therapeutic Area Unit GlaxoSmithKline 1996 ~ 1998 Postdoctoral research associate, Department of Chemistry, The Scripps Research Institute 1996 ~ 1998 Postdoctoral research associate, Department of Chemistry, The Scripps Research Institute, San Diego, CA 1996 ~ 1996 Postdoctoral research associate, Department of Chemistry, Purdue University 1989 ~ 1991 Research scientist, Korea Institute of Science and Technology (KIST)

<Education> DDS and PhD, Physiology, Pusan National University <Career> Head of Clinical Pharmacology at Yangsan Pusan National University Hospital President of Korean Society of Gene and Cell Therapy Director of MRC(medical research center) of PNU medical school Professor at Baylor School of Medicine and Dong-A University School of Medicine